ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Terremoto Biosciences has launched with $75 million in series A financing to discover small-molecule drugs using its lysine-targeted covalency technology. Terremoto says most drugs that bind to targets with covalent bonds attach to cysteine, which is uncommon in proteins. The South San Francisco–based firm says it has made breakthroughs in chemistry and biology allowing it to develop drugs that covalently bind to lysine, which is present in nearly every protein of interest.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter